296 related articles for article (PubMed ID: 35416593)
1. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
Luo MM; Zhu PP; Nnane I; Xiong Y; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Weiss BM; Tran N; Qin X; Vermeulen J; Sharma A; Sun YN; Zhou H
J Clin Pharmacol; 2022 May; 62(5):656-669. PubMed ID: 34708423
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K; Wechalekar AD; Kim K; Shimazaki C; Kim JS; Ikezoe T; Min CK; Zhou F; Cai Z; Chen X; Iida S; Katoh N; Fujisaki T; Shin HJ; Tran N; Qin X; Vasey SY; Tromp B; Weiss BM; Comenzo RL; Kastritis E; Lu J
Ann Hematol; 2023 Apr; 102(4):863-876. PubMed ID: 36862168
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.
Theodorakakou F; Dimopoulos MA; Kastritis E
Ther Adv Hematol; 2021; 12():20406207211058334. PubMed ID: 34840708
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.
Lamb YN
Drugs; 2020 Sep; 80(14):1455-1464. PubMed ID: 32936436
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
10. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
[TBL] [Abstract][Full Text] [Related]
11. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V; Palladini G; Minnema MC; Jaccard A; Lee HC; Gibbs S; Mollee P; Venner C; Lu J; Schönland S; Gatt M; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Chauveau D; Gries KS; Fastenau J; Tran NP; Qin X; Vasey SY; Weiss BM; Vermeulen J; Ho KF; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD
Am J Hematol; 2022 Jun; 97(6):719-730. PubMed ID: 35293006
[TBL] [Abstract][Full Text] [Related]
13. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Syed YY
Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
